Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Sep;78(3):243–249. doi: 10.1136/hrt.78.3.243

Long-term follow up of patients with implantable cardioverter-defibrillators and mild, moderate, or severe impairment of left ventricular function.

H J Trappe 1, P Wenzlaff 1, P Pfitzner 1, H G Fieguth 1
PMCID: PMC484925  PMID: 9391285

Abstract

OBJECTIVE: To determine whether patients with life threatening ventricular tachyarrhythmias, impaired left ventricular function, and severe heart failure will benefit from implantable cardioverter-defibrillator (ICD) treatment. DESIGN: 410 patients were followed up after ICD implant. Left ventricular function was assessed by the New York Heart Association (NYHA) functional class of heart failure: 50 patients (12%) were in NYHA I-II, 151 (37%) in NYHA II, 117 (29%) in NYHA II-III, and 92 (22%) in NYHA III. Epicardial ICD implantation was performed in 209 patients (51%) and 201 patients (49%) received non-thoracotomy ICDs. RESULTS: Perioperatively, 12 patients (3%) died, more often after epicardial ICD implant (11/209 patients, 5%) than after transvenous implant (1/201 patients, < 1%) (P < 0.05). During a mean (SD) follow up of 28 (24) months (range < 1 to 114 months), 90 patients (23%) died: nine (2%) died from sudden arrhythmia; five (1%) also died suddenly but probably not from arrhythmic causes; 55 (14%) died from cardiac causes (congestive heart failure, myocardial reinfarction); 21 (5%) died from non-cardiac causes. The three year, five year, and seven year survival was 92-96% for arrhythmic mortality in NYHA class I, II and III, compared to a three year survival of 94% and a five year and seven year survival of 84% for patients in NYHA class II-III. 338 patients (82%) received ICD shocks (21 (SD 43) shocks per patient); patients in NYHA class II (83%), class II-III (84%), and class III (90%) received ICD discharges more often than those in class I-II (64%) (P < 0.05). The mean (SD) time interval between ICD implant and the first ICD shock was shorter in NYHA class II (16 (17) months), class II-III (19 (27) months), and class III (16 (19) months) than in class 0-I (22 (24) months) (P < 0.05). CONCLUSIONS: Patients with mild, moderate, and severe left ventricular dysfunction benefit from ICD treatment and these patients survive for a considerable time after the first shock. Survival is influenced by the degree of left ventricular dysfunction; aggressive treatment of heart failure is necessary as well as ICD therapy.

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akhtar M., Jazayeri M., Sra J., Tchou P., Rovang K., Blanck Z., Dhala A., Deshpande S., Axtell K. Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation: ICD therapy in sudden cardiac death. Pacing Clin Electrophysiol. 1993 Mar;16(3 Pt 2):511–518. doi: 10.1111/j.1540-8159.1993.tb01618.x. [DOI] [PubMed] [Google Scholar]
  2. Axtell K., Tchou P., Akhtar M. Survival in patients with depressed left ventricular function treated by implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 1991 Feb;14(2 Pt 2):291–296. doi: 10.1111/j.1540-8159.1991.tb05109.x. [DOI] [PubMed] [Google Scholar]
  3. Axtell K., Tchou P., Akhtar M. Survival in patients with depressed left ventricular function treated by implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 1991 Feb;14(2 Pt 2):291–296. doi: 10.1111/j.1540-8159.1991.tb05109.x. [DOI] [PubMed] [Google Scholar]
  4. Böcker D., Block M., Isbruch F., Wietholt D., Hammel D., Borggrefe M., Breithardt G. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993 Jun;21(7):1638–1644. doi: 10.1016/0735-1097(93)90380-j. [DOI] [PubMed] [Google Scholar]
  5. Capucci A., Boriani G. Drugs, surgery, cardioverter defibrillator: a decision based on the clinical problem. Pacing Clin Electrophysiol. 1993 Mar;16(3 Pt 2):519–526. doi: 10.1111/j.1540-8159.1993.tb01619.x. [DOI] [PubMed] [Google Scholar]
  6. Cohn J. N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W. B., Loeb H., Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. doi: 10.1056/NEJM199108013250502. [DOI] [PubMed] [Google Scholar]
  7. Fogoros R. N., Elson J. J., Bonnet C. A., Fiedler S. B., Burkholder J. A. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol. 1990 Aug;16(2):381–386. doi: 10.1016/0735-1097(90)90590-l. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A., Wilen M., Ziesche S., Cohn J. N. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983 Mar 1;51(5):831–836. doi: 10.1016/s0002-9149(83)80141-6. [DOI] [PubMed] [Google Scholar]
  9. Furman S. AICD benefit. Pacing Clin Electrophysiol. 1989 Mar;12(3):399–400. doi: 10.1111/j.1540-8159.1989.tb02675.x. [DOI] [PubMed] [Google Scholar]
  10. Gillum R. F. Sudden coronary death in the United States: 1980-1985. Circulation. 1989 Apr;79(4):756–765. doi: 10.1161/01.cir.79.4.756. [DOI] [PubMed] [Google Scholar]
  11. Kim S. G., Fisher J. D., Choue C. W., Gross J., Roth J., Ferrick K. J., Brodman R., Furman S. Influence of left ventricular function on outcome of patients treated with implantable defibrillators. Circulation. 1992 Apr;85(4):1304–1310. doi: 10.1161/01.cir.85.4.1304. [DOI] [PubMed] [Google Scholar]
  12. Mehta D., Saksena S., Krol R. B., John T., Saxena A., Raju R., Kaushik R., Karanam R. Device use patterns and clinical outcome of implantable cardioverter defibrillator patients with moderate and severe impairment of left ventricular function. Pacing Clin Electrophysiol. 1993 Jan;16(1 Pt 2):179–185. doi: 10.1111/j.1540-8159.1993.tb01558.x. [DOI] [PubMed] [Google Scholar]
  13. Moss A. J. Prospective antiarrhythmic studies assessing prophylactic pharmacological and device therapy in high risk coronary patients. Pacing Clin Electrophysiol. 1992 Apr;15(4 Pt 3):694–696. doi: 10.1111/j.1540-8159.1992.tb05165.x. [DOI] [PubMed] [Google Scholar]
  14. Myerburg R. J., Luceri R. M., Thurer R., Cooper D. K., Zaman L., Interian A., Fernandez P., Cox M., Glicksman F., Castellanos A. Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989 Aug;14(2):508–514. doi: 10.1016/0735-1097(89)90209-x. [DOI] [PubMed] [Google Scholar]
  15. Nisam S., Kaye S. A., Mower M. M., Hull M. AICD automatic cardioverter defibrillator clinical update: 14 years experience in over 34,000 patients. Pacing Clin Electrophysiol. 1995 Jan;18(1 Pt 2):142–147. doi: 10.1111/j.1540-8159.1995.tb02493.x. [DOI] [PubMed] [Google Scholar]
  16. Schlepper M., Neuzner J., Pitschner H. F. Implantable cardioverter defibrillator: effect on survival. Pacing Clin Electrophysiol. 1995 Mar;18(3 Pt 2):569–578. doi: 10.1111/j.1540-8159.1995.tb02567.x. [DOI] [PubMed] [Google Scholar]
  17. Stevenson W. G., Stevenson L. W., Middlekauff H. R., Saxon L. A. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993 Dec;88(6):2953–2961. doi: 10.1161/01.cir.88.6.2953. [DOI] [PubMed] [Google Scholar]
  18. Swerdlow C. D., Winkle R. A., Mason J. W. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med. 1983 Jun 16;308(24):1436–1442. doi: 10.1056/NEJM198306163082402. [DOI] [PubMed] [Google Scholar]
  19. Tchou P. J., Kadri N., Anderson J., Caceres J. A., Jazayeri M., Akhtar M. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med. 1988 Oct 1;109(7):529–534. doi: 10.7326/0003-4819-109-7-529. [DOI] [PubMed] [Google Scholar]
  20. Trappe H. J., Klein H., Kielblock B. Role of antitachycardia pacing in patients with third generation cardioverter defibrillators. Pacing Clin Electrophysiol. 1994 Mar;17(3 Pt 2):506–513. doi: 10.1111/j.1540-8159.1994.tb01418.x. [DOI] [PubMed] [Google Scholar]
  21. Trappe H. J., Pfitzner P., Figuth H. G., Wenzlaff P., Kielblock B., Klein H. Nonpharmacological therapy of ventricular tachyarrhythmias: observations in 554 patients. Pacing Clin Electrophysiol. 1994 Nov;17(11 Pt 2):2172–2177. doi: 10.1111/j.1540-8159.1994.tb03821.x. [DOI] [PubMed] [Google Scholar]
  22. Trappe H. J., Wenzlaff P. Cardioverter defibrillator therapy as a bridge to heart transplantation. Pacing Clin Electrophysiol. 1995 Mar;18(3 Pt 2):622–631. doi: 10.1111/j.1540-8159.1995.tb02573.x. [DOI] [PubMed] [Google Scholar]
  23. Wilber D. J., Garan H., Finkelstein D., Kelly E., Newell J., McGovern B., Ruskin J. N. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med. 1988 Jan 7;318(1):19–24. doi: 10.1056/NEJM198801073180105. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES